<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732288</url>
  </required_header>
  <id_info>
    <org_study_id>NSC-0894</org_study_id>
    <nct_id>NCT02732288</nct_id>
  </id_info>
  <brief_title>Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury</brief_title>
  <official_title>Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with severe brain injuries often have slow accumulating recoveries of function. In
      ongoing studies, we have discovered that elements of electrical activity during sleep may
      correlate with the level of behavioral recovery observed in patients. It is unknown whether
      such changes are causally linked to behavioral recovery. Sleep processes are, however,
      associated with several critical processes supporting the cellular integrity of neurons and
      neuronal mechanisms associated with learning and synaptic modifications. These known
      associations suggest the possibility that targeting the normalization of brain electrical
      activity during sleep may aid the recovery process. A well-studied mechanism organizing the
      pattern of electrical activity that characterizes sleep is the body's release of the
      substance melatonin. Melatonin is produced in the brain and released at a precise time during
      the day (normally around 8-10PM) to signal the brain to initiate aspects of the sleep process
      each day. Ongoing research by other scientists has demonstrated that providing a small dose
      of melatonin can improve the regular pattern of sleep and help aid sleep induction. Melatonin
      use has been shown to be effective in the treatment of time change effects on sleep (&quot;jet
      lag&quot;) and mood disturbances associated with changes in daily light cues such as seasonal
      affective disorder. We propose to study the effects of melatonin administration in patients
      with severe structural brain injuries and disorders of consciousness. We will measure the
      patient's own timing of release of melatonin and provide a dose of melatonin at night to test
      the effects on the electrical activity of sleep over a three month period. In addition to
      brain electrical activity we will record sleep behavioral data and physical activity using
      activity monitors worn by the patients. Patient subjects in this study will be studied twice
      during the three month period in three day inpatient visits where they will undergo video
      monitoring and sampling of brain electrical activity using pasted electrodes (&quot;EEG&quot;), hourly
      saliva sampling for one day, and participation in behavioral testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe brain injuries often have slow accumulating recoveries of function.
      Recently, the National Institute for Disability and Rehabilitation Research (NIDRR) published
      data on their long-term outcomes of over 9,000 patients, 400 of which suffered disorders of
      consciousness (Nakase-Richardson et al. 2012). Patients were followed for 1, 2, and 5 year
      outcomes and several important and unexpected results were obtained: a large majority of
      patients initially in minimally conscious state (MCS) continued to improve recovering
      consciousness within a year and recovery was demonstrated to continue at the 2 and 5 year
      timepoints for as many as 20% of patients. In these cases outcomes included vocational
      reentry. Other studies have confirmed that MCS recovery can occur over long-time periods and
      lead to good outcomes or significant recovery of meaningful cognitive function despite
      enduring convalesce in MCS (Luaute et al. 2010, Lammi et al. 2005).

      In ongoing studies we have discovered that elements of electrical activity during sleep may
      correlate with the level of behavioral recovery observed in patients (Forgacs et al. 2014,
      Thengone et al. 2012). It is unknown, however, whether such changes are causally linked to
      behavioral recovery. Forgacs et al. 2014 showed a cross- sectional relationship between
      retention of key elements of sleep EEG architecture and behavioral level. Thengone et al.
      2012 correlated longitudinal changes in sleep architecture and quantitative spectral measures
      with behavioral recovery in 4 patients with severe brain injuries. No studies, however, have
      used an instrumental causal design to address whether improvement in sleep architecture can
      be promoted in patients with severe brain injuries and if so, whether or not changes in
      wakeful behavioral level are causally linked to such instrumentally generated changes in
      sleep.

      Sleep processes are associated with several critical processes supporting the cellular
      integrity of neurons and neuronal mechanisms associated with learning and synaptic
      modifications giving face validity to this approach. (Steriade, 1999; Tononi and Cirelli,
      2012). For example, studies in healthy volunteers (Huber et al. 2004) have provided evidence
      that local spindle density changes are associated with learning of specific information over
      sleep periods and can be topographically related to cortical populations engaged by the
      wakeful learning process. Additional evidence indicates that recovery of spindles within the
      electrical architecture of sleep is more associated with recovery of motor function in stroke
      (Gottselig, 2002). Collectively, although only a limited number of studies exist there is a
      biological basis for improvement in sleep architecture to potentially drive recovery and
      reorganization of brain networks organizing wakeful behavior.

      These known associations suggest the possibility that targeting the normalization of brain
      electrical activity during sleep may aid the recovery process. In fact, in one human subject
      studied here in our program, central thalamic deep brain stimulation (CT-DBS) applied
      beginning 20 years after severe traumatic brain injury (TBI) correlated with a normalization
      of sleep architecture beginning at the time after exposure to continuous DBS. These findings
      strongly suggest a link between increased driving of synaptic activity during the day and
      modification of sleep processes as this subject was only exposed to CT-DBS during daytime
      hours (Adams et al 2014). These findings improve the likelihood that there is a
      bi-directional causal relationship sleep dynamics and wakeful brain dynamics as linked to
      changes in behavior. Thus, the working hypothesis of the present study is that causal
      intervention to normalize sleep processes in patients with severe brain injuries may aid
      recovery of behavioral function.

      A well-studied mechanism organizing the normal patterns of electrical activity that
      characterizes sleep is the body's release of the substance melatonin. Melatonin is produced
      in the brain and released at a precise time during the day (normally around 8-10PM) to signal
      the brain to initiate aspects of the sleep process each day (Dijk, 1997). It is possible to
      exogenously trigger and drive melatonin signaling of sleep processes and initiation of sleep
      via oral dosing of the agent (Lewy et al. 1992). Use of oral melatonin supplements is common
      for pre- treatment of expected travel delay sleep disturbances (&quot;jet lag&quot;) and has been
      investigated in treatment of mood disorders (Lewy et al. 1996).

      Thus, we propose to study the effects of melatonin administration in patients with severe
      structural brain injuries and disorders of consciousness. An existing, though small,
      literature supports the probable success of this study; in neurodegenerative patients
      melatonin supplementation has shown modest benefit in improving some cognitive and
      noncognitive symptoms (Riemersma-van der Lek et al. 2008). Pediatric patients with traumatic
      brain injuries have been considered for treatment with melatonin based on similar
      considerations (Keegan et al. 2013)

      What will we do: We will measure the patient's own timing of release of melatonin and provide
      a dose of melatonin at a standard time at night (8PM) to test the effects on the electrical
      activity of sleep over a three month period. In addition to brain electrical activity, we
      will record sleep behavioral data and physical activity using activity monitors worn by the
      patients. Patient subjects in this study will be studied twice during the three month period
      in three day inpatient visits where they will undergo video monitoring and sampling of brain
      electrical activity using pasted electrodes (&quot;EEG&quot;), hourly saliva sampling for one day, and
      participate in behavioral testing.

      Why are the risks proportionate? Melatonin is very safe and has a limited and known adverse
      effect profile (Buscemi at al. 2004) Melatonin does not accumulate and can be stopped. We
      will carefully monitor the first dose during an in-patient stay. Moreover, from an ethical
      frame there is in this study a clear intention to treat. If our hypothesis is supported
      patients will meaningfully improve in function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in in sleep/wake architecture following melatonin administration as assessed by time domain analysis of sleep EEG</measure>
    <time_frame>baseline, 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quantitative measures of EEG spectral content</measure>
    <time_frame>baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in wakeful behavior level</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Scales include: Coma Recovery Scale (CRS) and Confusion Assessment Protocol (CAP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity levels captured by Actigraph device</measure>
    <time_frame>baseline, 3 months</time_frame>
    <description>Actigraph is a wearable motion detector used to monitor and track activity and sleep.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Disorders of Consciousness</condition>
  <arm_group>
    <arm_group_label>Melatonin, brain injured patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 3mg, orally, at 8pm, daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melatonin 3mg, orally, at 8pm</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.</description>
    <arm_group_label>Melatonin, brain injured patients</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for subjects:

          -  Subject's legally authorized representative must be fluent in English

          -  Subject must have been able to speak English prior to the brain injury occurrence

          -  Subject must have previously participated in the NSC-0764 study at Rockefeller
             University Hospital or New York Presbyterian-Cornell

          -  Subject must be diagnosed with a severe nonprogressive brain injury

          -  Subject must be medically stable

          -  Subject must be between 18 and 65 years of age

          -  Male and female subjects accepted

          -  Subject must have previously participated in studies with EEG data that identify
             elements of sleep architecture (evidence of components of at least 1 of the following:
             Stage 2 features (e.g. spindles K complexes, or vertex waves) or stage 3 features
             (e.g. slow waves), including the NSC-0764 study, and this data must be available to
             the PI.

        HEALTHY VOLUNTEERS: case matched to the study population +/- 5 years; fluent in English;
        ability to sit still for several consecutive hours; must sleep normal hours consistently
        (approximately 10 pm - about 6 am) and not be a shift worker

        Exclusion Criteria for subjects:

          -  Refractory generalized seizures

          -  Ventilator dependency

          -  Evidence of Alzheimer's Disease or dementia preinjury

          -  Currently taking melatonin

          -  Dialysis dependency

          -  Premorbid neuropsychiatric history (Axis I requiring prior hospitalization)

          -  History of severe asthma (requiring hospitalization)

          -  Participation in any investigational trial within 30 days prior to enrollment in this
             study

          -  History of any sleep disorder or restless leg syndrome pre-injury

          -  Medical history, physical examination, or laboratory findings suggestive of any other
             medical or psychological condition that would, in the opinion of the principal
             investigator, make the candidate ineligible for the study

        HEALTHY VOLUNTEERS: current or past medical history of any neurological disease or
        cardiovascular disease, sleep disorder, teeth grinding or restless leg syndrome (RLS);
        taking any medications with any neurologic effects, any medical condition that disrupts
        sleep; participation in NSC-0764; Body Mass Index (BMI) &gt; 30 kg/m2;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Schiff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medical College/ Rockefeller University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hersh, MBE</last_name>
    <phone>646-962-8032</phone>
    <email>jeh2015@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Rockefeller University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Luaut√© J, Maucort-Boulch D, Tell L, Quelard F, Sarraf T, Iwaz J, Boisson D, Fischer C. Long-term outcomes of chronic minimally conscious and vegetative states. Neurology. 2010 Jul 20;75(3):246-52. doi: 10.1212/WNL.0b013e3181e8e8df. Epub 2010 Jun 16.</citation>
    <PMID>20554940</PMID>
  </reference>
  <reference>
    <citation>Lammi MH, Smith VH, Tate RL, Taylor CM. The minimally conscious state and recovery potential: a follow-up study 2 to 5 years after traumatic brain injury. Arch Phys Med Rehabil. 2005 Apr;86(4):746-54.</citation>
    <PMID>15827927</PMID>
  </reference>
  <reference>
    <citation>Forgacs PB, Conte MM, Fridman EA, Voss HU, Victor JD, Schiff ND. Preservation of electroencephalographic organization in patients with impaired consciousness and imaging-based evidence of command-following. Ann Neurol. 2014 Dec;76(6):869-79. doi: 10.1002/ana.24283. Epub 2014 Oct 24.</citation>
    <PMID>25270034</PMID>
  </reference>
  <reference>
    <citation>Steriade M. Coherent oscillations and short-term plasticity in corticothalamic networks. Trends Neurosci. 1999 Aug;22(8):337-45. Review.</citation>
    <PMID>10407416</PMID>
  </reference>
  <reference>
    <citation>Tononi G, Cirelli C. Time to be SHY? Some comments on sleep and synaptic homeostasis. Neural Plast. 2012;2012:415250. doi: 10.1155/2012/415250. Epub 2012 Apr 29.</citation>
    <PMID>22619736</PMID>
  </reference>
  <reference>
    <citation>Huber R, Ghilardi MF, Massimini M, Tononi G. Local sleep and learning. Nature. 2004 Jul 1;430(6995):78-81. Epub 2004 Jun 6.</citation>
    <PMID>15184907</PMID>
  </reference>
  <reference>
    <citation>Nakase-Richardson R, Whyte J, Giacino JT, Pavawalla S, Barnett SD, Yablon SA, Sherer M, Kalmar K, Hammond FM, Greenwald B, Horn LJ, Seel R, McCarthy M, Tran J, Walker WC. Longitudinal outcome of patients with disordered consciousness in the NIDRR TBI Model Systems Programs. J Neurotrauma. 2012 Jan 1;29(1):59-65. doi: 10.1089/neu.2011.1829. Epub 2011 Aug 4.</citation>
    <PMID>21663544</PMID>
  </reference>
  <reference>
    <citation>Gottselig JM, Bassetti CL, Achermann P. Power and coherence of sleep spindle frequency activity following hemispheric stroke. Brain. 2002 Feb;125(Pt 2):373-83.</citation>
    <PMID>11844737</PMID>
  </reference>
  <reference>
    <citation>Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep EEG. J Biol Rhythms. 1997 Dec;12(6):627-35. Review.</citation>
    <PMID>9406038</PMID>
  </reference>
  <reference>
    <citation>Lewy AJ, Ahmed S, Jackson JM, Sack RL. Melatonin shifts human circadian rhythms according to a phase-response curve. Chronobiol Int. 1992 Oct;9(5):380-92.</citation>
    <PMID>1394610</PMID>
  </reference>
  <reference>
    <citation>Lewy AJ, Ahmed S, Sack RL. Phase shifting the human circadian clock using melatonin. Behav Brain Res. 1996;73(1-2):131-4. Review.</citation>
    <PMID>8788490</PMID>
  </reference>
  <reference>
    <citation>Riemersma-van der Lek RF, Swaab DF, Twisk J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA. 2008 Jun 11;299(22):2642-55. doi: 10.1001/jama.299.22.2642.</citation>
    <PMID>18544724</PMID>
  </reference>
  <reference>
    <citation>Keegan LJ, Reed-Berendt R, Neilly E, Morrall MC, Murdoch-Eaton D. Effectiveness of melatonin for sleep impairment post paediatric acquired brain injury: evidence from a systematic review. Dev Neurorehabil. 2014 Oct;17(5):355-62. doi: 10.3109/17518423.2012.741147. Epub 2013 Oct 8. Review.</citation>
    <PMID>24102301</PMID>
  </reference>
  <reference>
    <citation>Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for treatment of sleep disorders. Evid Rep Technol Assess (Summ). 2004 Nov;(108):1-7. Review.</citation>
    <PMID>15635761</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Nicholas Schiff</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Consciousness Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

